The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. (Q41712910)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

review article

1 reference

title

The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

1 reference

T N Chase

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

55 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

1-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9483164%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-199855001-00001

9 November 2019

exact match

0 references

cites work

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

1 reference

12 December 2020

Risk factors for motor response complications in L-dopa-treated parkinsonian patients

1 reference

12 December 2020

Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.

1 reference

12 December 2020

Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin

1 reference

12 December 2020

Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys

1 reference

12 December 2020

Parkinson's disease: from etiology to treatment

1 reference

12 December 2020

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

12 December 2020

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

12 December 2020

Neuroprotection by dopamine agonists.

1 reference

12 December 2020

Pathogenesis of dyskinesias in Parkinson's disease

1 reference

12 December 2020

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

12 December 2020

MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.

1 reference

12 December 2020

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

1 reference

12 December 2020

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease

1 reference

12 December 2020

Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat

1 reference

12 December 2020

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

12 December 2020

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

1 reference

12 December 2020

Oxidative stress and antioxidant therapy in Parkinson's disease

1 reference

12 December 2020

Acute pharmacologic blockade of dyskinesias in Parkinson's disease

1 reference

12 December 2020

Oxidative stress and Parkinson's disease.

1 reference

12 December 2020

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Cyclic adenosine-3',5'-monophosphate potentiates the synaptic potential mediated by NMDA receptors in the amygdala

1 reference

12 December 2020

Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease

1 reference

12 December 2020

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

1 reference

12 December 2020

Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.

1 reference

12 December 2020

NMDA receptor blockade reverses motor response alterations induced by levodopa

1 reference

12 December 2020

Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade

1 reference

12 December 2020

Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum

1 reference

12 December 2020

Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole

1 reference

12 December 2020

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys

1 reference

12 December 2020

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

12 December 2020

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

12 December 2020

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

1 reference

12 December 2020

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

1 reference

12 December 2020

The rationale for the use of dopamine agonists in Parkinson's disease

1 reference

12 December 2020

Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration

1 reference

12 December 2020

Oxidative stress and the pathogenesis of Parkinson's disease

1 reference

12 December 2020

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

1 reference

12 December 2020

The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists

1 reference

12 December 2020

Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys

1 reference

12 December 2020

Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.

1 reference

12 December 2020

N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease

1 reference

12 December 2020